Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658415 | 0.87 | ESR1 (0.56) | CYP1A2SLC7A5TAAR1ALDH1A1CYP3A4 | |
| SCHEMBL7452482 | 0.87 | EPHX1 (0.42) | EPHX1ALDH1A1HTTSMN1; SMN2CYP3A4 | |
| SCHEMBL11754330 | 0.82 | ALDH1A1 (0.54) | ACP3CYP1A2ALDH1A1CYP2D6TSHR | |
| SCHEMBL11754323 | 0.82 | LDHA (0.51) | EPHX1ACP3SLC6A4CYP1A2ALDH1A1 | |
| SCHEMBL28313381 | 0.81 | TACR1 (0.42) | SLC6A2SLC6A4SLC6A3CYP1A2SIGMAR1 | |
| SCHEMBL9852879 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3SIGMAR1CYP3A4 | |
| SCHEMBL22798139 | 0.79 | CYP1A2 (0.48) | EPHX1SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL5249350 | 0.78 | ESR1 (0.60) | EPHX1ACP3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL56063 | 0.78 | ESR2 (0.60) | EPHX1ACP3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8712988 | 0.76 | LMNA (0.46) | TAAR1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997045119-A1 | USE OF SUBSTANCE P ANTAGONISTS FOR TREATING SOCIAL PHOBIA | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | claimed |
| US-5416118-A | Enzyme inhibitors | SCHERING CORPORATION (US) | 1995-05-16 | — | — | US | claimed |
| US-5326762-A | Heterocyclic substituted amides | SCHERING CORPORATION (US) | 1994-07-05 | — | — | US | claimed |
| EP-0583346-A1 | BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE | SCHERING CORPORATION (US) | 1994-02-23 | — | — | EP | claimed |
| WO-1992018462-A1 | BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0508425-A1 | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase | SCHERING CORPORATION (US) | 1992-10-14 | — | — | EP | claimed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2316824-A1 | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-0984778-A4 | NEUROPEPTIDE-Y LIGANDS | ALANEX CORP (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0984778-A1 | NEUROPEPTIDE-Y LIGANDS | Alanex Corporation (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998007420-A1 | NEUROPEPTIDE-Y LIGANDS | AGOURON ACQUISITION CORP. (US) | 1998-02-26 | — | — | WO | disclosed |
| US-5149709-A | Treatment of atherosclerosis | SCHERING CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0441226-A1 | (cyanomethyl)pyridines useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1991-08-14 | — | — | EP | disclosed |
| US-4927565-A | HYPOTENSIVE AGENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0367227-A2 | Silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4851387-A | RENIN INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0272583-A2 | 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | EPHX1 975/4885ACP3 1184/4885SLC6A2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.